Tirzepatide
Mounjaro, ZEPBOUND
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
NADAC/unit
$525.8889
No Shortage
Tier 1: 111.2%
PA Req: 590.6%
ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or ad....
vs. brand Mounjaro: Generic saves up to -5159% per unit
Generic Manufacturers
ELI LILLY AND CO
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.